LivaNova PLC 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. LivaNova PLC is a global medical technology company operating in two segments: Cardiopulmonary (heart-lung machines, oxygenators) and Neuromodulation (VNS Therapy for epilepsy and depression, sleep apnea devices). The company is a large accelerated filer listed on Nasdaq (LIVN).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $362.3 million | $316.9 million |
| Gross Profit | $243.7 million | $216.3 million |
| Gross Margin | 67.3% | 68.2% |
| Operating Income | $41.5 million | $48.6 million |
| Net Income | $22.3 million | ($327.3 million) Loss |
| Diluted EPS | $0.40 | ($6.01) |
| Operating Cash Flow | $15.2 million | $24.0 million |
| Cash & Equivalents | $539.7 million | $738.4 million |
| Total Debt Obligations | $287.8 million | $376.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 14.3% year-over-year, driven by 18.3% growth in Cardiopulmonary (strong Essenz system sales) and 9.3% growth in Neuromodulation.
- Profitability Turnaround: The company returned to profitability ($22.3M net income) compared to a significant loss in Q1 2025. The prior year loss was heavily impacted by a one-time $360.4 million SNIA environmental liability expense recorded in Q1 2025 following an Italian Supreme Court decision. No such charge was recorded in Q1 2026.
- Expense Increases: R&D expenses rose 55% to $58.7 million, primarily due to $8.9 million in contingent consideration adjustments for the ImThera acquisition and $5.5 million in OSA device development. SG&A increased but improved as a percentage of revenue due to fixed cost leverage.
- Debt Reduction: Total debt decreased by approximately $89 million due to the full early repayment of Term Facilities ($95.9 million) in January 2026.
Outlook, Risks, and Unusual Items
- Regulatory Milestone: On March 18, 2026, the FDA granted Premarket Approval (PMA) for the aura6000 System for treating obstructive sleep apnea (OSA).
- SNIA Litigation Status: While the major liability was recognized in 2025, the case remains active. The Italian Court of Appeal scheduled a hearing for June 24, 2026, to discuss a potential out-of-court resolution. The company maintains a liability reserve of $389.5 million.
- Product Liability: Ongoing litigation regarding the 3T Heater-Cooler device continues, with a provision of $12.6 million as of March 31, 2026.
- Derivatives: Significant volatility in fair value adjustments for the 2029 Embedded Derivative and Capped Calls impacted "Foreign exchange and other income/(expense)," resulting in a $5.7 million net expense for the quarter.
- Iran Disclosure: The company reported $1.6 million in gross revenue from sales to distributors in Iran, consistent with applicable sanctions laws.
Investor Verification Checklist
- SNIA Liability Resolution: Verify the outcome of the June 2026 Court of Appeal hearing regarding the potential settlement of the SNIA environmental liability.
- ImThera Contingent Consideration: Monitor the impact of the regulatory milestone achievement on future cash payments and fair value adjustments.
- Debt Structure: Confirm the terms and interest rates of the remaining 2029 Notes ($280.2 million principal) and the status of the revolving credit facility.
- 3T Litigation: Track the number of filed claims and the adequacy of the $12.6 million provision against potential future settlements.
- Revenue Quality: Assess the sustainability of the 18.3% Cardiopulmonary growth rate and the contribution of the newly approved aura6000 system to future Neuromodulation revenue.